Immunological mechanisms of hepatitis B virus persistence in newborns

Indian Journal of Medical Research

Volumn 138, Issue NOV, 2013, Pages 700-710

  Trehanpati, Nirupma ^a   Hissar, Syed ^a   Shrivastav, Shikha ^a   Sarin, Shiv Kumar ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

Chronic infection; HbeAg; HbsAg; Hepatitis B virus (HBV); Perinatal; Pregnancy

Indexed keywords

ADEFOVIR; EMTRICITABINE; ESTROGEN; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PROGESTERONE; T LYMPHOCYTE RECEPTOR; TELBIVUDINE; TENOFOVIR; VIRUS ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT; HLA ANTIGEN; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; BIRTH DEFECT; CD8+ T LYMPHOCYTE; DISEASE CARRIER; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HLA SYSTEM; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; INTRAUTERINE INFECTION; LACTATION; META ANALYSIS (TOPIC); NONHUMAN; PERSISTENT VIRUS INFECTION; PREGNANCY; PRENATAL SCREENING; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; VERTICAL TRANSMISSION; VIRUS LOAD; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; IMMUNOPATHOGENESIS; NEWBORN; PRENATAL EXPOSURE; THIRD TRIMESTER PREGNANCY; VACCINATION; VIRUS CARRIER; VIRUS TRANSMISSION;

FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNE TOLERANCE; INFANT, NEWBORN; INTERFERON-GAMMA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; T-LYMPHOCYTES, REGULATORY;

EID: 84891711404     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. World Health Organization: Hepatitis B: World Health Organization fact sheet No 204 (July 2012). Available from: http://www.who. int/ mediacentre/ factsheets/ fs204/en, accessed on July 1, 2012.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
3. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15 (Supp): E3-6.
4. Chatterjee S, Ravishankar K, Chatterjee R, Narang A, Kinikar A. Hepatitis B Prevalence during pregnancy. Indian Pediatr 2009; 46: 1005-8.
5. Hissar S, Sarin SK, Kumar M, Kazim SN, Tarun KG, Pande C, et al. Transmission of hepatitis B virus infection is predominantly perinatal in the Indian subcontinent. Gastroenterology 2011; 140: S-723.
6. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332: 328-36.
7. Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, et al. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987; 316: 965-70.
8. Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Sytematic review and meta-analysis of prevalence of hepatitis B in India. Indian Pediatr 2007; 44: 663-74.
9. Pande C, Sarin SK, Patra S, Bhutia K, Mishra SK, Pahuja S, et al. Prevalence, risk factors and virological profile of chronic hepatitis B virus infection in pregnant women in India. J Med Virol 2011; 83: 962-7.
10. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis 2007; 11: 945-63.
11. Lao T, Chan B, Leung W, Ho L, Tse K. Maternal hepatitis B infection and gestational diabetes mellitus. J Hepatol 2007; 47: 46-50.
12. Elefsiniotis IS, Papadakis M, Vlahos G, Daskalakis G, Saroglou G, Antsaklis A. Clinical significance of hepatitis B surface antigen in cord blood of hepatitis B e-antigen-negative chronic hepatitis B virus-infected mothers. Intervirology 2009; 52: 132-4.
13. Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190: 489-92.
14. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38: 1075-86.
15. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Jones J, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004; 101: 14913-8.
16. Zhu Q, Yu G, Yu H, Lu Q, Gu X, Dong Z, et al. A randomized control trial on interruption of HBV transmission in uterus. Chin Med J 2003; 116: 685-7.
17. Wang JS, Zhu QR. Infection of the fetus with hepatitis B eantigen via the placenta. Lancet 2000; 355: 989.
18. Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of HBV DNA level and HBeAg titer inhepatitis B surface antigen positive mothers and their babies:HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003; 71: 360-6.
19. Vranckx R, Alisjahbana A, Meheus A. Hepatitis B virus vaccination and antenatal transmission of HBV markers to neonates. J Viral Hepat 1999; 6: 135-9.
20. Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002; 67: 20-6.
21. Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zheng JX, et al. Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol 2011; 83: 791-5.
22. Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission of hepatitis B virus in North India. J Med Virol 1987; 21: 137-45.
23. Mittal SK, Rao S, Rastogi A, Aggarwal V, Kumari S. Hepatitis B-potential of perinatal transmission in India. Trop Gastroenterol 1996; 17: 190-2.
24. Pavel A, Tirsia E, Maior E, Cristea A. Detrimental effects of hepatitis B virus infection on the development of the product of conception. Virologie 1983; 34: 35-40.
25. Wong S, Chan LY, Yu V, Ho L. Hepatitis B carrier and perinatal outcome in singleton pregnancy. Am J Perinatol 1999; 16: 485-8.
26. Safir A, Levy A, Sikuler E, Sheiner E. Maternal hepatitis B virus or hepatitis C virus carrier status as an independent risk factor for adverse perinatal outcome. Liver Int 2010; 30: 765-70.
27. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005; 43: 771-5.
28. Singh AE, Plitt SS, Osiowy C, Surynicz K, Kouadjo E, Preiksaitis J, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat 2011; 18: 468-73.
29. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 1452-7.
30. Broderick AL, Jonas MM. Hepatitis B in children. Semin Liver Dis 2003; 23: 59-68.
31. Dusheiko G. Interruption of mother-to-infant transmission of hepatitis B: time to include selective antiviral prophylaxis? Lancet 2012; 379: 2019-21.
32. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis 2012; 16: e82-8.
33. Tacke F, Amini-Bavil-Olyaee S, Heim A, Luedde T, Manns MP, Trautwein C. Acute hepatitis B virus infection by genotype F despite successful vaccination in an immunecompetent German patient. J Clin Virol 2007; 38: 353-7.
34. Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990; 8 (Suppl): S129-33.
35. Pande C, Sarin SK, Patra S, Kumar A, Mishra S, Srivastava S, et al. Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: randomized controlled trial. J Viral Hepat 2013; 20: 801-10.
36. Buchanan C, Tran TT. Management of chronic hepatitis B in pregnancy. Clin Liver Dis 2010; 14: 495-504.
37. Chang M-H. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007; 12: 160-7.
38. Boland GJ, Veldhuijzen IK, Janssen HLA, van der Eijk AA, Wouters MGAJ, Boot HJ. Management and treatment of pregnant women with hepatitis B. Ned Tijdschr Geneeskd 2009; 153: A905.
39. Tan H, Lui H, Chow W. Chronic hepatitis B virus (HBV) infection in pregnancy. Hepatol Int 2008; 2: 370-5.
40. Hung JH, Chu CJ, Sung PL, Chen CY, Chao KC, Yang MJ, et al. Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy. J Chin Med Assoc 2008; 71: 155-8.
41. Xie Y, Li M. Antiviral treatment for pregnant women with chronic HBV infection. Zhonghua Gan Zang Bing Za Zhi 2010; 18: 486-7.
42. Bacq Y. Hepatitis B and pregnancy. Gastroenterol Clin Biol 2008; 32: S12-9.
43. Van Zonneveld M, van Nunen AB, Niesters HGM, de Man RA, Schalm SW, Janssen HLA. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-7.
44. Chotiyaputta W, Lok AS. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat 2009; 16: 91-3.
45. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002; 99: 1049-52.
46. Johnson MA, Moore KH, Yuen GJ, Bye A, Pakes GE. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36: 41-66.
47. Van Rompay KK, Hamilton M, Kearney B, Bischofberger N. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother 2005; 49: 2093-4.
48. Benaboud S, Pruvost A, Coffie PA, Ekouevi DK, Urien S, Arrive E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother 2011; 55: 1315-7.
49. Pazmany L, Mandelboim O, Valés-Gómez M, Davis DM, Reyburn HT, Strominger JL. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 1996; 274: 792-5.
50. Jonas M, Block JM, Haber BA, Karpen SJ, London WT, Murray KF. Treatment of children with chronic hepatitis B virus infection in the United States: Patient selection and therapeutic options. Hepatology 2010; 52: 2192-205.
51. Angel Garcia AL. Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann Hepatol 2006; 5: 184-6.
52. Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver Transpl 2008; 14: 1081-91.
53. Trowsdale J, Betz AG. Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006; 7: 241-6.
54. Druckmann R, Druckmann MA. Progesterone and the immunology of pregnancy. J Steroid Biochem Mol Biol 2005; 97: 389-96.
55. Szekeres-Bartho J, Halasz M, Palkovics T. Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol 2009; 83: 60-4.
56. Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18: 478-82.
57. Piccinni MP, Scaletti C, Maggi E, Romagnani S. Role of hormone-controlled Th1-and Th2-type cytokines in successful pregnancy. J Neuroimmunol 2000; 109: 30-3.
58. Miller L, Hunt JS. Sex steroid hormones and macrophage function. Life Sci 1996; 1-14.
59. Zuckerman SH, Bryan-Poole N, Evans GF, Short L, Glasebrook AL. In vivo modulation of marine serum tumour necrosis factor and interleukin-6 levels during endotoxemia by oestrogen agonists and antagonists. Immunology 1995; 18-24.
60. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-gamma promoter. J Immunol 1991; 146: 4362-7.
61. Maret A, Coudert JD, Garidou L, Foucras G, Gourdy P, Krust A, et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo, Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003; 33: 512-21.
62. ter Borg MJ, Leemans WF, de Man RA, Janssen HLA. Exacerbation of chronic hepatitis B infection after delivery. J Vir Hepat 2008; 15: 37-41.
63. Yang Y-B, Li X-M, Shi Z-J, Ma L. Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report. World J Gastroenterol 2004; 10: 2305-6.
64. Jonas MM. Hepatitis B and pregnancy: An underestimated issue. Liver Intl 2009; 29: 133-9.
65. Tagawa H, Suzuki K, Oh S, Kawano M, Fujita A, Yasuhi Y, et al. Influence of pregnancy on HB virus carriers. Nippon Sanka Fujinka Gakkai Zasshi 1987; 39: 24-30.
66. Lin HH, Wu WY, Kao JH, Cehn DS. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: correlation with viral characteristics. J Gastroenterol Hepatol 2006; 21: 605-9.
67. Trehanpati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, et al. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol 2011; 31: 509-20.
68. Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology 1995; 22: 1387-92.
69. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005; 43: 771-5.
70. Athanassakis I, Vassiliadis S. Interplay between T helper type 1 and type 2 cytokines and soluble major histocompatibility complex molecules: a paradigm in pregnancy. Immunology 2002; 107: 281-7.
71. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111 (Suppl 2): S460-75.
72. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14: 353-6.
73. Mjösberg J, Berg G, Ernerudh J, Ekerfelt C. CD4+ CD25+ regulatory T cells in human pregnancy: development of a Treg-MLC-ELISPOT suppression assay and indications of paternal specific Tregs. Immunology 2007; 120: 456-66.
74. Somerset DA, Zheng Y, Kilby MD, Sansom DM, Drayson MT. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+CD4+ regulatory T-cell subset. Immunology 2004; 112: 38-43.
75. Stoop JN, van der Molen RG, Baan CC, van der Laan LJW, Kuipers EJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771-8.
76. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol 2005; 43: 771-5.
77. ter Borg MJ, Leemans WF, de Man RA, Janssen HLA. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15: 37-41.
78. Shrivastava S, TrehanPati N, Khanam A, Pande C, Patra S, Trivedi S, et al. Hepatitis B virus mediated down regulated expression of CD3 ζ is associated with phenotypic and functionally defective T cells in HBV infected newborns. Hepatology 2010; 52 (Suppl): 365A.
79. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4: 841-55.
80. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603-6.
81. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells inimmunological tolerance to self and non-self. Nat Immunol 2005; 6: 345-52.
82. Gammon G, Dunn K, Shastri N, Oki A, Wilbur S, Sercarz EE. Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation. Nature 1986; 319: 413-5.
83. Schmielau J, Nalesnik MA, Finn OJ. Suppressed T-cell receptor ζ chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001; 7: 933S-9S.
84. Schule J, Bergkvist L, Hakansson L, Gustafsson B, Hakansson A. Down-regulation of the CD3ζ chain in sentinel node biopsies from breast cancer patients. Breast Cancer Res Treat 2002; 74: 33-40.
85. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111: 460-75.
86. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL, et al. The good, the bad, and the ugly." The role of chemokines in models of human disease. J Immunol 1996; 156: 3583-6.
87. Johnston RB. Function and cell biology of neutrophils and mononuclear phagocytes in the newborn infant. Vaccine 1998; 16: 1363-8.
88. Schelonka R L, and Infante AJ 1998. Neonatal immunology. Semin Perinatol 1998; 22: 2-14.
89. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2011; 19: 3331-46.
90. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-202.
91. Moir S, Ho J, Malaspina A, Wang W, Di Poto AC, O'Shea MA, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected individuals. J Exp Med 2008; 205: 1797-805.
92. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9: 235-45.
93. Shrivastava S, Trehanpati N, Kottilil S, Sarin SK. Decline in immature transitional B cells after hepatitis B vaccination in hepatitis B positive newborns. Pediatr Infect Dis J 2013; 32: 792-4.